Marinomed Biotech AG (WBO:MARI) Shareholder Yield % : 93.19% (As of Dec. 2025)


WBO:MARI Marinomed Biotech AG WBO:MARI
42 GF Score
Price €9.45
GF Value €18.66
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Shareholder Yield %?

Marinomed Biotech AG WBO:MARI 42 Shareholder Yield % is 93.19% as of Dec. 2025. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.66 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,295 Biotechnology companies, Marinomed Biotech AG ranks better than 99.23% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Marinomed Biotech AG's Shareholder Yield % was 93.19%.


Marinomed Biotech AG  (WBO:MARI) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Marinomed Biotech AG Shareholder Yield % Related Terms


Marinomed Biotech AG Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Shareholder Yield % Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.61 -9.59 3.78 -28.81 50.10

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 -13.65 -28.81 15.23 50.10

WBO:MARI vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Marinomed Biotech AG's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinomed Biotech AG Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's Shareholder Yield % falls into.


WBO:MARI
42GF Score
Marinomed Biotech AG WBO:MARI
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Shareholder Yield % Calculation

Marinomed Biotech AG's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+50.1 %
=50.1 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 93.19% mean?
Marinomed Biotech AG (WBO:MARI) has a Shareholder Yield % of 93.19% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #10 out of 1295 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Marinomed Biotech AG's Shareholder Yield % too high?
Marinomed Biotech AG's current Shareholder Yield % is 93.19%. Based on the distribution chart, Marinomed Biotech AG ranks #10 out of 1295 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #10 out of 1295 companies for Shareholder Yield %. This places Marinomed Biotech AG in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Shareholder Yield % is 93.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.66, compared to a current price of €9.45 — trading 49.4% below its estimated fair value. The current Shareholder Yield % is 93.19%. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Shareholder Yield % is 93.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €9.45 is trading 49.4% below its estimated GF Value™ of €18.66. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Shareholder Yield %: 93.19%
  • GF Value™: €18.66 vs. price of €9.45 (49.4% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score

Get the complete analysis for WBO:MARI

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.45
Price
€18.66
GF Value